Abstract
Combinations of dacarbazine (DTIC) and other cytotoxic agents or alpha-interferon were given to 136 patients in five different regimens. The total response rate was 32% (95% confidence interval 24-40%); 13% had a complete remission. Female patients had a significantly higher chance of response than male patients: 46% vs 23%. There was also a difference in complete response rate: 25% vs 9%. The overall survival was 6 months; 8% of patients had a response of more than 6 months and 2% of more than 2 years. Although response rates vary among the various regimens described in the literature, the complete response rates are quite similar and the long-term disease-free survival of these combinations may be similar to that of dacarbazine alone.
Publication types
-
Clinical Trial
-
Controlled Clinical Trial
MeSH terms
-
Adolescent
-
Adult
-
Aged
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Bleomycin / administration & dosage
-
Combined Modality Therapy
-
Dacarbazine / administration & dosage*
-
Dacarbazine / adverse effects
-
Dactinomycin / administration & dosage
-
Female
-
Granulocyte Colony-Stimulating Factor / administration & dosage
-
Humans
-
Immunotherapy*
-
Interferon-alpha / administration & dosage
-
Male
-
Melanoma / drug therapy*
-
Melanoma / therapy*
-
Middle Aged
-
Treatment Outcome
-
Vinblastine / administration & dosage
Substances
-
Interferon-alpha
-
Bleomycin
-
Granulocyte Colony-Stimulating Factor
-
Dactinomycin
-
Vinblastine
-
Dacarbazine